Allotera Therapeutics (formerly Wugen) is advancing Soficabtagene Geleucel (Sofi-cel), a CD7-targeted allogeneic, off-the-shelf CAR-T cell therapy for T-cell malignancies. Sofi-cel is manufactured from healthy donor T cells in the United States and uses CRISPR/Cas9 to delete CD7 and TRAC to reduce fratricide and graft-versus-host disease risk. Sofi-cel is being evaluated in a global pivotal T-RRex clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (ClinicalTrials.gov identifier NCT06514794). The therapy has received multiple regulatory designations, including Breakthrough Therapy, RMAT, Fast Track, Orphan Drug, Rare Pediatric Disease in the U.S., and PRIME in the EU. The company says its approach aims to address biological and manufacturing barriers in T-cell CAR-T development and is using recent financing to support pivotal development, manufacturing scale-up, platform advancement, and team growth. Allotera is headquartered in St. Louis.

Total raised

$322M

Funding rounds

4

Latest round

Series C

Latest activity

Jul 2026